慢性肾脏病血液透析患者促红细胞生成素用药途径疗效对比

Efficacy comparison of different route of administration erythropoietin in chronic kidney disease patients with hemodialysis

目的对比慢性肾脏病血液透析患者促红细胞生成素用药途径的疗效。方法按照随机分组原则,将168例慢性肾脏病血液透析患者分为静脉注射组和皮下注射组,每组84例,初始剂量为5900~6000 U/周,分为2次进行。连续治疗12周,之后监测患者的血红蛋白（Hb）、肾功能、血电解质以及丙氨酸氨基转移酶（ALT）等水平的变化情况。结果皮下注射组患者用药有效率为90.48%（76/84）,静脉注射组为71.43%（60/84）,两组比较差异有统计学意义（P〈0.05）。结论慢性肾脏病血液透析患者应用皮下注射的方式治疗肾性贫血症状,疗效更佳。

Objective To compare the effect of different route of administration erythropoietin（ EPO） on chronic kidney disease（ CKD） patients with hemodialysis. Methods According to the principle of randomization,168 CKD patients with hemodialysis were divided into intravenous group and subcutaneous group with 84 cases in each group. The initial dose of EPO was5900- 6000 U / week,divided into 2 times,continuous treatment for 12 weeks. The changes of Hb,renal function,serum electrolytes and the level of ALT were monitored. Results The medication effective rate was 90. 48%（ 76 /84） in subcutaneous group and 71. 43%（ 60 /84） in intravenous group,the difference between the two groups was significant（ P〈0. 05）.Conclusion The effect of subcutaneous injection of EPO on CKD patients with hemodialysis is better.